Hansoh Pharma's HS-20122 Posts 61.3% Response Rate in EGFR-Mutant Lung Cancer Phase 1

Hansoh Pharma presented Phase 1 results for HS-20122 at ESMO in Madrid on October 24, 2026, showing a 61.3% response rate in EGFR-mutant lung cancer after TKI failure. The future of trading reported the results. The drug showed antitumor activity across advanced solid tumors, with manageable safety.

Hansoh's HS-20122 Phase 1 Data at ESMO

Hansoh Pharmaceutical Group Co. Ltd. Is a Shanghai-based drugmaker whose pipeline spans oncology, metabolic disease and antibody-drug conjugates. The company published the original content behind the ESMO presentation.

The Phase 1 trial evaluated HS-20122 in patients with advanced solid tumors, with particular activity in EGFR-mutated lung cancer following failure of EGFR-targeted therapy. Safety was manageable, and most treatment-related adverse events were mild to moderate. Serious events primarily involved blood abnormalities. The findings support further development in multiple solid tumors, including EGFR-mutated lung cancer.

Roche Deal and Earlier Hansoh Readouts

Hansoh Pharmaceutical and Roche entered a partnership and licensing deal worth over $15 billion covering antibody-drug conjugate programs, EIN Presswire reported in October 2026. Hansoh receives an upfront $400 million and a first anniversary payment of $110 million, with further milestone payments.

Hansoh Pharma presented Phase III data for its dual-biased GLP-1/GIP agonist Olatorepatide at EASD 2026, showing mean weight loss of 19.3% at week 48 in the 15 mg group versus 2.7% in placebo, PR Newswire reported in October 2026. On September 2, 2026, Hansoh Pharmaceutical announced that its injectable HS-20093 (Risvutatug Rezetecan) for adult small cell lung cancer patients who failed platinum-based therapy was accepted for marketing authorization by China's National Medical Products Administration, Jiemian reported.

Other ESMO 2026 Readouts

Johnson & Johnson announced new PROTEUS substudy results showing apalutamide plus androgen deprivation therapy before and after surgery reduced recurrence or death risk by 62% versus surgery alone in high-risk prostate cancer, PR Newswire reported on October 24, 2026.

Quanta Therapeutics presented positive clinical data for QTX3034 combined with cetuximab and/or chemotherapy in KRAS G12D-mutant colorectal cancer at ESMO 2026, showing a 25% overall response rate and 75% disease control, GlobeNewswire reported. CatalYm presented final results from its Phase 2 GDFATHER-NEO trial at ESMO 2026, showing visugromab plus nivolumab improved pathologic complete response (33% vs 8%) in neoadjuvant bladder cancer, FinancialContent Business Page reported.

What Comes Next for HS-20122

The findings support further development of HS-20122 in multiple solid tumors, including EGFR-mutated lung cancer. Quanta Therapeutics' QTX6255, a pan-KRAS inhibitor, is advancing toward an IND filing in 4Q26, GlobeNewswire reported.